Weight beneficial treatments for type 2 diabetes

Journal of Clinical Endocrinology and Metabolism

Volumn 96, Issue 11, 2011, Pages 3337-3353

  Meneghini, Luigi F ^a   Orozco Beltran, D ^b   Khunti, K ^c   Caputo, S ^d   Damci T ^e   Liebl, A ^f   Ross, S A ^g  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b MIGUEL HERNÁNDEZ UNIVERSITY   (Spain)

^c UNIVERSITY OF LEICESTER   (United Kingdom)

^d CATHOLIC UNIVERSITY   (Italy)

^e ISTANBUL UNIVERSITY   (Turkey)

^f Center for Diabetes and Metabolism   (Germany)

^g UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; COLESEVELAM; EXENDIN 4; GLIBENCLAMIDE; GLIMEPIRIDE; GLUCOSE; HEMOGLOBIN A1C; INSULIN ASPART; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN LISPRO; ISOPHANE INSULIN; LIRAGLUTIDE; METFORMIN; MIGLITOL; PIOGLITAZONE; PLACEBO; PRAMLINTIDE; ROSIGLITAZONE; SAXAGLIPTIN; SITAGLIPTIN; SULFONYLUREA;

ADD ON THERAPY; BEDTIME DOSAGE; BODY MASS; CARDIOVASCULAR DISEASE; DIET RESTRICTION; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG TREATMENT FAILURE; EVENING DOSAGE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; INSULIN TREATMENT; LIFESTYLE MODIFICATION; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SYSTEMATIC REVIEW; TREATMENT RESPONSE; WEIGHT GAIN; WEIGHT REDUCTION;

BODY WEIGHT; DIABETES MELLITUS, TYPE 2; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; METFORMIN; OBESITY; WEIGHT LOSS;

EID: 80655137229     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2011-1074     Document Type: Review

References (126)

1. Bolen S, Feldman L, Vassy J, Wilson L, Yeh HC, Marinopoulos S, Wiley C, Selvin E, Wilson R, Bass EB, Brancati FL 2007 Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Ann Intern Med 147:386-399 (Pubitemid 351664540)
2. Schmid C, Krayenbühl P, Wiesli P 2009 Increased insulin dose requirement of long-acting insulin analogues in obese patients with type 2 diabetes. Diabetologia 52:2668-2669
3. González-Sánchez JL, Serrano-Ríos M 2007 Molecular basis of insulin action. Drug News Perspect 20:527-531 (Pubitemid 351182796)
4. Bonora E 2007 Antidiabetic medications in overweight/obese patients with type 2 diabetes: drawbacks of current drugs and potential advantages of incretin-based treatment on body weight. Int J Clin Pract Suppl 154:19-28 (Pubitemid 46934643)
5. Hermansen K, Mortensen LS 2007 Bodyweight changes associated with antihyperglycaemic agents in type 2 diabetes mellitus. Drug Saf 30:1127-1142 (Pubitemid 350172854)
6. Krentz AJ 2008 Managementof type 2 diabetes in the obese patient: current concerns and emerging therapies. Curr Med Res Opin 24:401-417 (Pubitemid 351294390)
7. DeFronzo RA, Stonehouse AH, Han J, Wintle ME 2010 Relationship of baseline HbA1c and efficacy of current glucose-lowering therapies: a meta-analysis of randomized clinical trials. Diabet Med 27:309-317
8. American Diabetes Association 2008 Standards of medical care in diabetes-2008. Diabetes Care 31(Suppl 1):S12-S54
9. American Diabetes Association 2010 Standards of medical care in diabetes-2010. Diabetes Care 33(Suppl 1):S11-S61
10. Rydén L, Standl E, Bartnik M, Van den Berghe G, Betteridge J, de Boer MJ, Cosentino F, Jönsson B, Laakso M, Malmberg K, Priori S, Ostergren J, Tuomilehto J, Thrainsdottir I, Vanhorebeek I, Stramba-Badiale M, Lindgren P, Qiao Q, Priori SG, Blanc JJ, Budaj A, Camm J, Dean V, Deckers J, Dickstein K, Lekakis J, McGregor K, Metra M, Morais J, Osterspey A, Tamargo J, Zamorano JL, Deckers JW, Bertrand M, Charbonnel B, Erdmann E, Ferrannini E, Flyvbjerg A, Gohlke H, Juanatey JR, Graham I, Monteiro PF, Parhofer K, Pyörälä K, Raz I, Schernthaner G, Volpe M, Wood D2007 Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 28:88-136 (Pubitemid 46137814)
11. UK Prospective Diabetes Study (UKPDS) Group 1998 Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352:854-865
12. DeFronzo RA, Goodman AM 1995 Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. N Engl J Med 333:541-549
13. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, Kravitz BG, Lachin JM, O'Neill MC, Zinman B, Viberti G 2006 Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 355:2427-2443 (Pubitemid 44903747)
14. Schernthaner G, Matthews DR, Charbonnel B, Hanefeld M, Brunetti P 2004 Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial. J Clin Endocrinol Metab 89:6068-6076 (Pubitemid 39628416)
15. Stewart MW, Cirkel DT, Furuseth K, Donaldson J, Biswas N, Starkie MG, Phenekos C, Hamann A 2006 Effect of metformin plus roziglitazone compared with metformin alone on glycaemic control in well-controlled type 2 diabetes. Diabet Med 23:1069-1078 (Pubitemid 44401135)
16. Phung OJ, Scholle JM, Talwar M, Coleman CI 2010 Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes. JAMA 303:1410-1418
17. DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD 2005 Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 28:1092-1100 (Pubitemid 40616618)
18. Ratner RE, Maggs D, Nielsen LL, Stonehouse AH, Poon T, Zhang B, Bicsak TA, Brodows RG, Kim DD 2006 Long-term effects of exenatide therapy over 82 weeks on glycaemic control and weight in over-weight metformin-treated patients with type 2 diabetes mellitus. Diabetes Obes Metab 8:419-428 (Pubitemid 44349234)
19. Nauck M, Frid A, Hermansen K, Shah NS, Tankova T, Mitha IH, Zdravkovic M, Düring M, Matthews DR 2009 Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care 32:84-90
20. Goldstein BJ, Feinglos MN, Lunceford JK, Johnson J, Williams-Herman DE 2007 Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care 30:1979-1987 (Pubitemid 47219404)
21. DeFronzo RA, Hissa MN, Garber AJ, Luiz Gross J, Yuyan Duan R, Ravichandran S, Chen RS 2009 The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone. Diabetes Care 32:1649-1655
22. Klonoff DC, Buse JB, Nielsen LL, Guan X, Bowlus CL, Holcombe JH, Wintle ME, Maggs DG 2008 Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin 24:275-286 (Pubitemid 351160260)
23. Buse JB, Rosenstock J, Sesti G, Schmidt WE, Montanya E, Brett JH, Zychma M, Blonde L 2009 Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallelgroup, multinational, open-label trial (LEAD-6). Lancet 374:39-47
24. Kendall DM, Riddle MC, Rosenstock J, Zhuang D, Kim DD, Fineman MS, Baron AD 2005 Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 28:1083-1091 (Pubitemid 40616617)
25. Nauck MA, Duran S, Kim D, Johns D, Northrup J, Festa A, Brodows R, Trautmann M 2007 A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. Diabetologia 50:259-267
26. Bergenstal R, Lewin A, Bailey T, Chang D, Gylvin T, Roberts V 2009 Efficacy and safety of biphasic insulin aspart 70/30 versus exenatide in subjects with type 2 diabetes failing to achieve glycemic control with metformin and a sulfonylurea. Curr Med Res Opin 25:65-75
27. Zinman B, Gerich J, Buse JB, Lewin A, Schwartz S, Raskin P, Hale PM, Zdravkovic M, Blonde L 2009 Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met-TZD). Diabetes Care 32:1224-1230
28. Russell-Jones D, Vaag A, Schmitz O, Sethi BK, Lalic N, Antic S, Zdravkovic M, Ravn GM, Simó R 2009 Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met-SU): a randomised controlled trial. Diabetologia 52:2046-2055
29. Barnett AH, Burger J, Johns D, Brodows R, Kendall DM, Roberts A, Trautmann ME 2007 Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial. Clin Ther 29:2333-2348 (Pubitemid 350298125)
30. Heine RJ, Van Gaal LF, Johns D, Mihm MJ, Widel MH, Brodows RG 2005 Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 143:559-569
31. Kirkman MS, McCarren M, Shah J, Duckworth W, Abraira C 2006 The association between metabolic control and prevalent macrovascular disease in type 2 diabetes: the VA cooperative study in diabetes. J Diabetes Complications 20:75-80
32. Standl E, Müller M, Schnell O 2009 The impact of glucose-lowering therapy on cardiovascular outcomes. Best Pract Res Clin Endocrinol Metab 23:401-411
33. Goudswaard AN, Furlong NJ, Rutten GE, Stolk RP, Valk GD 2004 Insulin monotherapy versus combinations of insulin with oral hypoglycaemic agents in patients with type 2 diabetes mellitus. Cochrane Database Syst Rev 4:CD003418
34. Hannele Yki-Järvinen H, Kauppila M, Kujansuu E, Lahti J, Marjanen T, Niskanen L, Rajala S, Ryysy L, Salo S, Seppälä P, Tulokas T, Viikari J, Karjalainen J, Taskinen MR 1992 Comparison of insulin regimens in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 327:1426-1433
35. Chow CC, Tsang LW, Sorensen JP, Cockram CS 1995 Comparison of insulin with or without continuation of oral hypoglycemic agents in the treatment of secondary failure in NIDDM patients. Diabetes Care 18:307-314
36. Yki-Järvinen H, Dressler A, Ziemen M 2000 Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group. Diabetes Care 23:1130-1136 (Pubitemid 30616801)
37. Pradhan AD, Everett BM, Cook NR, Rifai N, Ridker PM 2009 Effects of initiating insulin and metformin on glycemic control and inflammatory biomarkers among patients with type 2 diabetes: the LANCET randomized trial. JAMA 302:1186-1194
38. Yki-Järvinen H, Kauppinen-Mäkelin R, Tiikkainen M, Vähätalo M, Virtamo H, Nikkilä K, Tulokas T, Hulme S, Hardy K, McNulty S, Hänninen J, Levänen H, Lahdenperä S, Lehtonen R, Ryysy L 2006 Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study. Diabetologia 49:442-451 (Pubitemid 43277866)
39. Fajardo Montañana C, Hernández Herrero C, Rivas Fernández M 2008 Less weight gain and hypoglycaemia with once-daily insulin detemir than NPH insulin in intensification of insulin therapy in overweight type 2 diabetes patients: the PREDICTIVE BMI clinical trial. Diabet Med 25:916-923
40. Malone JK, Bai S, Campaigne BN, Reviriego J, Augendre-Ferrante B 2005 Twice-daily pre-mixed insulin rather than basal insulin therapy alone results in better overall glycaemic control in patients with type 2 diabetes. Diabet Med 22:374-381 (Pubitemid 40516233)
41. Robbins DC, Beisswenger PJ, Ceriello A, Goldberg RB, Moses RG, Pagkalos EM, Milicevic Z, Jones CA, Sarwat S, Tan MH 2007 Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison. Clin Ther 29:2349-2364
42. Holman RR, Thorne KI, Farmer AJ, Davies MJ, Keenan JF, Paul S, Levy JC 2007 Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med 357:1716-1730 (Pubitemid 350005153)
43. Holman RR, Farmer AJ, Davies MJ, Levy JC, Darbyshire JL, Keenan JF, Paul SK 2009 Three-year efficacy of complex insulin regimens in type 2 diabetes. N Engl J Med 361:1736-1747
44. Lund SS, Tarnow L, Frandsen M, Nielsen BB, Hansen BV, Pedersen O, Parving HH, Vaag AA 2009 Combining insulin with metformin or an insulin secretagogue in non-obese patients with type 2 diabetes: 12 month, randomised, double blind trial. BMJ 339:b4324
45. Garber AJ 2011 Long-acting glucagon-like peptide 1 receptor agonists: a review of their efficacy and tolerability. Diabetes Care 34(Suppl 2):S279-S284
46. Moretto TJ, Milton DR, Ridge TD, Macconell LA, Okerson T, Wolka AM, Brodows RG 2008 Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 30:1448-1460
47. Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD 2004 Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 27:2628-2635 (Pubitemid 39441462)
48. Fakhoury WK, Lereun C, Wright D 2010 A meta-analysis of placebo-controlled clinical trials assessing the efficacy and safety of incretin-based medications in patients with type 2 diabetes. Pharmacology 86:44-57
49. Pratley RE, Gilbert M 2008 Targeting incretins in type 2 diabetes: role of GLP-1 receptor agonists and DPP-4 inhibitors. Rev Diabet Stud 5:73-94
50. Garber A, Henry R, Ratner R, Garcia-Hernandez PA, Rodriguez-Pattzi H, Olvera-Alvarez I, Hale PM, Zdravkovic M, Bode B 2009 Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 373:473-481
51. Marre M, Shaw J, Brändle M, Bebakar WM, Kamaruddin NA, Strand J, Zdravkovic M, Le Thi TD, Colagiuri S 2009 Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU). Diabet Med 26:268-278
52. Seino Y, Rasmussen MF, Nishida T, Kaku K 2010 Efficacy and safety of the once-daily human GLP-1 analogue, liraglutide, vs glibenclamide monotherapy in Japanese patients with type 2 diabetes. Curr Med Res Opin 26:1013-1022
53. Aschner P, Kipnes MS, Lunceford JK, Sanchez M, Mickel C, Williams-Herman DE 2006 Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 29:2632-2637 (Pubitemid 44912190)
54. Rosenstock J, Aguilar-Salinas C, Klein E, Nepal S, List J, Chen R 2009 Effect of saxagliptin monotherapy in treatment-naive patients with type 2 diabetes. Curr Med Res Opin 25:2401-2411
55. Rosenstock J, Brazg R, Andryuk PJ, Lu K, Stein P 2006 Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 28:1556-1568 (Pubitemid 44841980)
56. Hollander P, Li J, Allen E, Chen R 2009 Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone. J Clin Endocrinol Metab 94:4810-4819
57. Hermansen K, Kipnes M, Luo E, Fanurik D, Khatami H, Stein P 2007 Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes Obes Metab 9:733-745 (Pubitemid 47261855)
58. Chacra AR, Tan GH, Apanovitch A, Ravichandran S, List J, Chen R 2009 Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial. Int J Clin Pract 63:1395-1406
59. Van de Laar FA, Lucassen PL, Akkermans RP, Van de Lisdonk EH, Rutten GE, Van Weel C 2005 α-Glucosidase inhibitors for type 2 diabetes mellitus. Cochrane Database Syst Rev 2:CD003639
60. Laube H 2002 Acarbose: an update of its therapeutic use in diabetes treatment. Clin Drug Invest 22:141-156 (Pubitemid 34275772)
61. Bays HE, Goldberg RB, Truitt KE, Jones MR 2008 Colesevelam hydrochloride therapy in patients with type 2 diabetes mellitus treated with metformin: glucose and lipid effects. Arch Intern Med 168:1975-1983
62. Fonseca VA, Rosenstock J, Wang AC, Truitt KE, Jones MR 2008 Colesevelam HCl improves glycemic control and reduces LDL cholesterol in patients with inadequately controlled type 2 diabetes on sulfonylurea-based therapy. Diabetes Care 31:1479-1484
63. Goldberg RB, Fonseca VA, Truitt KE, Jones MR 2008 Efficacy and safety of colesevelam in patients with type 2 diabetes mellitus and inadequate glycemic control receiving insulin-based therapy. Arch Intern Med 168:1531-1540
64. Staels B, Kuipers F 2007 Bile acid sequestrants and the treatment of type 2 diabetes mellitus. Drugs 67:1383-1392 (Pubitemid 47026388)
65. Hollander PA, Levy P, Fineman MS, Maggs DG, Shen LZ, Strobel SA, Weyer C, Kolterman OG 2003 Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial. Diabetes Care 26:784-790 (Pubitemid 36929344)
66. Riddle M, Pencek R, Charenkavanich S, Lutz K, Wilhelm K, Porter L 2009 Randomized comparison of pramlintide or mealtime insulin added to basal insulin treatment for patients with type 2 diabetes. Diabetes Care 32:1577-1582
67. Aronne L, Fujioka K, Aroda V, Chen K, Halseth A, Kesty NC, Burns C, Lush CW, Weyer C 2007 Progressive reduction in body weight after treatment with the amylin analog pramlintide in obese subjects: a phase 2, randomized, placebo-controlled, dose-escalation study. J Clin Endocrinol Metab 92:2977-2983 (Pubitemid 47236359)
68. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B 2009 Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 32:193-203
69. Jacob AN, Salinas K, Adams-Huet B, Raskin P 2007 Weight gain in type 2 diabetes mellitus. Diabetes Obes Metab 9:386-393 (Pubitemid 46502059)
70. Edgerton DS, Ramnanan CJ, Grueter CA, Johnson KM, Lautz M, Neal DW, Williams PE, Cherrington AD 2009 Effects of insulin on the metabolic control of hepatic gluconeogenesis in vivo. Diabetes 58:2766-2775
71. Ramnanan CJ, Edgerton DS, Rivera N, Irimia-Dominguez J, Farmer B, Neal DW, Lautz M, Donahue EP, Meyer CM, Roach PJ, Cherrington AD 2010 Molecular characterization of insulin-mediated suppression of hepatic glucose production in vivo. Diabetes 59:1302-1311
72. Mäkimattila S, Nikkilä K, Yki-Järvinen H 1999 Causes of weight gain during insulin therapy with and without metformin in patients with type II diabetes mellitus. Diabetologia 42:406-412 (Pubitemid 29148398)
73. Monami M, Marchionni N, Mannucci E 2008 Long-acting insulin analogues versus NPH human insulin in type 2 diabetes: a meta-analysis. Diabetes Res Clin Pract 81:184-189
74. Raslová K, Bogoev M, Raz I, Leth G, Gall MA, Hâncu N 2004 Insulin detemir and insulin aspart: a promising basal-bolus regimen for type 2 diabetes. Diabetes Res Clin Pract 66:193-201 (Pubitemid 39469347)
75. Haak T, Tiengo A, Draeger E, Suntum M, Waldhäusl W 2005 Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes. Diabetes Obes Metab 7:56-64
76. Hermansen K, Davies M, Derezinski T, Martinez Ravn G, Clauson P, Home P 2006 A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care 29:1269-1274 (Pubitemid 44125921)
77. Fonseca V, Bell DS, Berger S, Thomson S, Mecca TE 2004 A comparison of bedtime insulin glargine with bedtime neutral protamine hagedorn insulin in patients with type 2 diabetes: subgroup analysis of patients taking once-daily insulin in a multicenter, randomized, parallel group study. Am J Med Sci 328:274-280 (Pubitemid 39518531)
78. Raslová K, Tamer SC, Clauson P, Karl D 2007 Insulin detemir results in less weight gain than NPH insulin when used in basal-bolus therapy for type 2 diabetes mellitus, and this advantage increases with baseline body mass index. Clin Drug Investig 27:279-285 (Pubitemid 46440300)
79. Mandosi E, Fallarino M, Rossetti M, Gatti A, Morano S 2009 Waist circumference reduction after insulin detemir therapy in type 2 diabetes patients previously treated with NPH. Diabetes Res Clin Pract 84:e18-e20
80. Blonde L, Merilainen M, Karwe V, Raskin P 2009 Patient-directed titration for achieving glycaemic goals using a once-daily basal insulin analogue: an assessment of two different fasting plasma glucose targets - the TITRATE study. Diabetes Obes Metab 11:623-631
81. Meneghini LF, Dornhorst A, Sreenan S 2009 Once-daily insulin detemir in a cohort of insulin-naive patients with type 2 diabetes: a sub-analysis from the PREDICTIVE study. Curr Med Res Opin 25:1029-1035
82. Khunti K, Srinivasan BT, Shutler S, Davies MJ 2010 Effect of insulin glargine on glycaemic control and weight in obese and non-obese people with type 2 diabetes: data from the AT.LANTUS trial. Diabetes Obes Metab 12:683-688
83. Philis-Tsimikas A, Charpentier G, Clauson P, Ravn GM, Roberts VL, Thorsteinsson B 2006 Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes. Clin Ther 28:1569-1581 (Pubitemid 44856694)
84. Davies MJ, Derezinski T, Pedersen CB, Clauson P 2008 Reduced weight gain with insulin detemir compared to NPH insulin is not explained by a reduction in hypoglycemia. Diabetes Technol Ther 10:273-277
85. Rosenstock J, Davies M, Home PD, Larsen J, Koenen C, Schernthaner G 2008 A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetologia 51:408-416
86. Raskin P, Gylvin T, Weng W, Chaykin L 2009 Comparison of insulin detemir and insulin glargine using a basal-bolus regimen in a randomized, controlled clinical study in patients with type 2 diabetes. Diabetes Metab Res Rev 25:542-548
87. Fakhoury W, Lockhart I, Kotchie RW, Aagren M, LeReun C 2008 Indirect comparison of once daily insulin detemir and glargine in reducing weight gain and hypoglycaemic episodes when administered in addition to conventional oral anti-diabetic therapy in patients with type-2 diabetes. Pharmacology 82:156-163
88. Dailey G, Admane K, Mercier F, Owens D 2010 Relationship of insulin dose, A1C lowering, and weight in type 2 diabetes: comparing insulin glargine and insulin detemir. Diabetes Technol Ther 12:1019-1027
89. Hollander P, Raslova K, Skjoth TV, Rastam J, Luitkus JF 2010 Once-daily insulin detemir in combination with sitagliptin/metformin offers improved glycemic control versus sitagliptin/metformin ± sulphonylurea drugs. Diabetes 59:Abstract 549-P
90. Buse JB, Bergenstal RM, Glass LC, Heilmann CR, Lewis MS, Kwan AY, Hoogwerf BJ, Rosenstock J 2011 Use of twice-daily exenatide in basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial. Ann Intern Med 154:103-112
91. Hollander P, Raslova K, Skjøth TV, Råstam J, Liutkus JF 2011 Efficacy and safety of insulin detemir once daily in combination with sitagliptin and metformin: the TRANSITION randomized controlled trial. Diabetes Obes Metab 13:268-275
92. The Diabetes Control and Complications Trial Research Group 1993 The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977-986
93. UK Prospective Diabetes Study (UKPDS) Group 1998 Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet [Erratum (1999) 354:602] 352:837-853
94. Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, Kojima Y, Furuyoshi N, Shichiri M 1995 Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 28:103-117
95. Krolewski AS, Laffel LM, Krolewski M, Quinn M, Warram JH 1995 Glycosylated hemoglobin and the risk of microalbuminuria in patients with insulin-dependent diabetes mellitus. N Engl J Med 332:1251-1255
96. The Diabetes Control and Complications (DCCT) Research Group 1995 Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. Kidney Int 47:1703-1720
97. Viberti GA 1995 Glycemic threshold for diabetic complications? N Engl J Med 332:1293-1294
98. Huang ES, Liu JY, Moffet HH, John PM, Karter AJ 2011 Glycemic control, complications, and death in older diabetic patients: the diabetes and aging study. Diabetes Care 34:1329-1336
99. Opie LH, Yellon DM, Gersh BJ 2011 Controversies in the cardiovascular management of type 2 diabetes. Heart 97:6-14
100. Evangelista LS, Heber D, Li Z, Bowerman S, Hamilton MA, Fonarow GC 2009 Reduced body weight and adiposity with a highprotein diet improves functional status, lipid profiles, glycemic control, and quality of life in patients with heart failure: a feasibility study. J Cardiovasc Nurs 24:207-215
101. Williamson DA, Rejeski J, Lang W, Van Dorsten B, Fabricatore AN, Toledo K; Look AHEAD Research Group 2009 Impact of a weight management program on health-related quality of life in overweight adults with type 2 diabetes. Arch Intern Med 169:163-171
102. Vijan S, Stuart NS, Fitzgerald JT, Ronis DL, Hayward RA, Slater S, Hofer TP 2005 Barriers to following dietary recommendations in type 2 diabetes. Diabet Med 22:32-38 (Pubitemid 40188283)
103. Rodbard HW, Jellinger PS, Davidson JA, Einhorn D, Garber AJ, Grunberger G, Handelsman Y, Horton ES, Lebovitz H, Levy P, Moghissi ES, Schwartz SS 2009 Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract 15:540-559
104. Drucker DJ, Buse JB, Taylor K, Kendall DM, Trautmann M, Zhuang D, Porter L 2008 Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet 372:1240-1250
105. Buse JB, Drucker DJ, Taylor KL, Kim T, Walsh B, Hu H, Wilhelm K, Trautmann M, Shen LZ, Porter LE 2010 DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks. Diabetes Care 33:1255-1261
106. Nauck M, Marre M 2009 Adding liraglutide to oral antidiabetic drug monotherapy: efficacy and weight benefits. Postgrad Med 121:5-15
107. Pratley RE, Nauck M, Bailey T, Montanya E, Cuddihy R, Filetti S, Thomsen AB, Søndergaard RE, Davies M 2010 Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. Lancet 375:1447-1456
108. Malone JK, Kerr LF, Campaigne BN, Sachson RA, Holcombe JH 2004 Combined therapy with insulin lispro Mix 75/25 plus metformin or insulin glargine plus metformin: a 16-week, randomized, open-label, crossover study in patients with type 2 diabetes beginning insulin therapy. Clin Ther 26:2034-2044 (Pubitemid 40353613)
109. Janka HU, Plewe G, Riddle MC, Kliebe-Frisch C, Schweitzer MA, Yki-Järvinen H 2005 Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes. Diabetes Care 28:254-259 (Pubitemid 40170922)
110. Raskin P, Matfin G, Schwartz SL, Chaykin L, Chu PL, Braceras R, Wynne A 2009 Addition of biphasic insulin aspart 30 to optimized metformin and pioglitazone treatment of type 2 diabetes mellitus: the ACTION Study (Achieving Control Through Insulin plus Oral ageNts). Diabetes Obes Metab 11:27-32
111. Seino Y, Rasmussen MF, Zdravkovic M, Kaku K 2008 Dose-dependent improvement in glycemia with once-daily liraglutide without hypoglycemia or weight gain: a double-blind, randomized, controlled trial in Japanese patients with type 2 diabetes. Diabetes Res Clin Pract 81:161-168
112. Swinnen SG, Dain MP, Aronson R, Davies M, Gerstein HC, Pfeiffer AF, Snoek FJ, Devries JH, Hoekstra JB, Holleman F 2010 A 24-week, randomized, treat-to-target trial comparing initiation of insulin glargine once-daily with insulin detemir twice-daily in patients with type 2 diabetes inadequately controlled on oral glucose-lowering drugs. Diabetes Care 33:1176-1178
113. Rosenstock J, Schwartz SL, Clark Jr CM, Park GD, Donley DW, Edwards MB 2001 Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care 24:631-636 (Pubitemid 32888839)
114. Rosenstock J, Sugimoto D, Strange P, Stewart JA, Soltes-Rak E, Dailey G 2006 Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients. Diabetes Care 29:554-559 (Pubitemid 44115353)
115. Kennedy L, Herman WH, Strange P, Harris A 2006 Impact of active versus usual algorithmic titration of basal insulin and point-of-care versus laboratory measurement of HbA1c on glycemic control in patients with type 2 diabetes: the Glycemic Optimization with Algorithms and Labs at Point of Care (GOAL A1C) trial. Diabetes Care 29:1-8 (Pubitemid 44033422)
116. Riddle MC, Rosenstock J, Gerich J 2003 The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 26:3080-3086 (Pubitemid 37339502)
117. Massi Benedetti M, Humburg E, Dressler A, Ziemen M 2003 A one-year, randomised, multicentre trial comparing insulin glargine with NPH insulin in combination with oral agents in patients with type 2 diabetes. Horm Metab Res 35:189-196 (Pubitemid 36577862)
118. Kacerovsky-Bielesz G, Dressler A, Freunscht R 2006 Long-term glycaemic control with insulin glargine in type 2 diabetes. Diabetes Res Clin Pract 71:184-191 (Pubitemid 43112111)
119. Bretzel RG, Nuber U, Landgraf W, Owens DR, Bradley C, Linn T 2008 Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial. Lancet 371:1073-1084 (Pubitemid 351436611)
120. Buse JB, Wolffenbuttel BH, Herman WH, Shemonsky NK, Jiang HH, Fahrbach JL, Scism-Bacon JL, Martin SA 2009 DURAbility of basal versus lispro mix 75/25 insulin efficacy (DURABLE) trial 24-week results: safety and efficacy of insulin
121. Davies M, Storms F, Shutler S, Bianchi-Biscay M, Gomis R 2005 Improvement of glycemic control in subjects with poorly controlled type 2 diabetes: comparison of two treatment algorithms using insulin glargine. Diabetes Care 28:1282-1288 (Pubitemid 40756686)
122. Davies M, Evans R, Storms F, Gomis R, Khunti K 2007 Initiation of insulin glargine in suboptimally controlled patients with type 2 diabetes: sub-analysis of the AT.LANTUS trial comparing treatment outcomes in subjects from primary and secondary care in the UK. Diabetes Obes Metab 9:706-713 (Pubitemid 47261852)
123. Pan CY, Sinnassamy P, Chung KD, Kim KW 2007 Insulin glargine versus NPH insulin therapy in Asian type 2 diabetes patients. Diabetes Res Clin Pract 76:111-118 (Pubitemid 46240371)
124. Fritsche A, Schweitzer MA, Häring HU 2003 Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial. Ann Intern Med 138:952-959
125. Hollander P, Cooper J, Bregnhøj J, Pedersen CB 2008 A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes. Clin Ther 30:1976-1987
126. Ushakova O, Sokolovskaya V, Morozova A, Valeeva F, Zanozina O, Sazonova O, Zhadanova E, Starceva M, Kazakova E, Saifullina M, Shapiro I, Tarasov A, Al-Tayar B, Starkova N 2007 Comparison of biphasic insulin aspart 30 given three times daily or twice daily in combination with metformin versus oral antidiabetic drugs alone in patients with poorly controlled type 2 diabetes: a 16-wk, randomized, open-label, parallel-group trial conducted in Russia. Clin Ther 29:2374-2384